Literature DB >> 29470775

Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit.

Joana Simões-Pereira1, Joaquim Nunes2, Ana Aguiar2, Sandra Sousa2, Cátia Rodrigues2, Joaquim Sampaio Matias3, Carlos Calhaz-Jorge2.   

Abstract

PURPOSE: Anti-Müllerian hormone (AMH) is a useful marker of ovarian reserve. Obesity/overweight are increasing and may affect the reproductive health. Previous studies regarding the effect of body mass index (BMI) on AMH levels are discordant. Our main goal was to evaluate the influence of BMI on AMH levels in women without polycystic ovarian syndrome.
METHODS: Revision of medical records of 951 women who performed AMH determinations as part of their fertility workup, between 2011 and 2016.
RESULTS: Median AMH concentration was 1.75 [interquartile range (IQR) 2] ng/mL (12.9 pmol/mL) and median age at AMH determination was 35 (IQR 6) years. These women evidenced a median BMI of 23 (IQR 5) kg/m2. Caucasian women were more represented [889(89.3%)]. Smoking habits (present/past) were present in 359(36.1%), and 147(14.8%) harboured a history of ovarian surgery. On univariable analysis AMH was not correlated with BMI (r = 0.048/p = 0.135); the only factors influencing AMH were age (p < 0.001), ethnicity (p = 0.004), and previous ovarian surgery (p < 0.001). On multivariable analysis, age was the only variable significantly associated with AMH, evidencing a reduction of 6.2% for each additional year (p < 0.0001). Furthermore, we verified a trend suggesting an AMH reduction of 22% (p = 0.08) in black patients comparing with the caucasian ones, when controlling for the other variables.
CONCLUSION: We report one of the largest series evaluating the influence of BMI on AMH levels and, consequently, on ovarian reserve. BMI does not seem to affect AMH levels. The reported concerns on infertility in overweight and obese women may be related to follicular development/oocyte maturation or endometrial disorders, rather than decreased ovarian reserve.

Entities:  

Keywords:  Anti-Müllerian hormone; Body mass index; Obesity; Ovarian reserve; Polycystic ovarian syndrome

Mesh:

Substances:

Year:  2018        PMID: 29470775     DOI: 10.1007/s12020-018-1555-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  19 in total

1.  Association between BMI and gene expression of anti-Müllerian hormone and androgen receptor in human granulosa cells in women with and without polycystic ovary syndrome.

Authors:  Mohammad Nouri; Esmat Aghadavod; Sajad Khani; Mehri Jamilian; Mehrnush Amiri Siavashani; Shahnaz Ahmadi; Zatollah Asemi
Journal:  Clin Endocrinol (Oxf)       Date:  2016-06-02       Impact factor: 3.478

Review 2.  American Society for Metabolic and Bariatric Surgery position statement on the impact of obesity and obesity treatment on fertility and fertility therapy Endorsed by the American College of Obstetricians and Gynecologists and the Obesity Society.

Authors:  Michelle A Kominiarek; Emily S Jungheim; Kathleen M Hoeger; Ann M Rogers; Scott Kahan; Julie J Kim
Journal:  Surg Obes Relat Dis       Date:  2017-02-12       Impact factor: 4.734

3.  Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women.

Authors:  M Stracquadanio; L Ciotta; M A Palumbo
Journal:  Gynecol Endocrinol       Date:  2017-09-23       Impact factor: 2.260

4.  Is there any correlation between amh and obesity in premenopausal women?

Authors:  Sezai Sahmay; Taner Usta; Cemal Tamer Erel; Metehan Imamoğlu; Mustafa Küçük; Nil Atakul; Hakan Seyisoğlu
Journal:  Arch Gynecol Obstet       Date:  2012-05-04       Impact factor: 2.344

Review 5.  Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.

Authors:  Jenny A Visser; Izaäk Schipper; Joop S E Laven; Axel P N Themmen
Journal:  Nat Rev Endocrinol       Date:  2012-01-10       Impact factor: 43.330

6.  Association of anti-mullerian hormone levels with obesity in late reproductive-age women.

Authors:  Ellen W Freeman; Clarisa R Gracia; Mary D Sammel; Hui Lin; Lony Chong-Leong Lim; Jerome F Strauss
Journal:  Fertil Steril       Date:  2006-11-15       Impact factor: 7.329

7.  Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history.

Authors:  Luciano G Nardo; Dimitra Christodoulou; Della Gould; Steve A Roberts; Cheryl T Fitzgerald; Ian Laing
Journal:  Gynecol Endocrinol       Date:  2007       Impact factor: 2.260

8.  Effects of obesity on assisted reproductive technology outcomes.

Authors:  Robert J Norman; Lindsay R Chura; Rebecca L Robker
Journal:  Fertil Steril       Date:  2007-06-04       Impact factor: 7.329

Review 9.  Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review.

Authors:  Agathe Dumont; Geoffroy Robin; Sophie Catteau-Jonard; Didier Dewailly
Journal:  Reprod Biol Endocrinol       Date:  2015-12-21       Impact factor: 5.211

10.  Effect of Female Body Mass Index on Oocyte Quantity in Fertility Treatments (IVF): Treatment Cycle Number Is a Possible Effect Modifier. A Register-Based Cohort Study.

Authors:  Mette Wulf Christensen; Hans Jakob Ingerslev; Birte Degn; Ulrik Schiøler Kesmodel
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

View more
  8 in total

1.  The relationship between anti-Müllerian hormone serum level and body mass index in a large cohort of infertile patients.

Authors:  Dragos Albu; Alice Albu
Journal:  Endocrine       Date:  2018-09-20       Impact factor: 3.633

2.  Diminished Ovarian Reserve in Girls and Adolescents with Trisomy X Syndrome.

Authors:  Shanlee M Davis; Katelyn Soares; Susan Howell; Melanie Cree-Green; Eliza Buyers; Joshua Johnson; Nicole R Tartaglia
Journal:  Reprod Sci       Date:  2020-06-23       Impact factor: 3.060

3.  The Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients with Different Subgroups.

Authors:  Yu Ran; Qiang Yi; Cong Li
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-25       Impact factor: 3.168

4.  Anti-Müllerian Hormone Predictive Levels to Determine The Likelihood of Ovarian Hyper-Response in Infertile Women with Polycystic Ovarian Morphology.

Authors:  Azadeh Akbari Sene; Mahnaz Ashrafi; Nasim Alaghmand-Fard; Neda Mohammadi; Mona Mortezapour Alisaraie; Ahad Alizadeh
Journal:  Int J Fertil Steril       Date:  2021-03-11

5.  The status and comparison of ovarian reserve between fertile and infertile healthy Chinese women of reproductive age.

Authors:  Shan-Jie Zhou; Tie-Cheng Sun; Ling-Li Song; Ming Yang; Xin-Ping Sun; Li Tian
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

6.  Determination of 12 anti-obesity drugs in human plasma by a 96-well protein precipitation plate using HPLC-MS.

Authors:  Tengteng Ping; Min Zheng; Pingping Zhang; Tianhao Yan; Xufeng Miao; Ke Wang; Kaoqi Lian
Journal:  RSC Adv       Date:  2022-09-13       Impact factor: 4.036

7.  Association of body mass index with serum anti-Müllerian hormone and inhibin B levels among 8323 women attending a reproductive medical center: a cross-sectional study.

Authors:  Yaqi Wang; Li Wu; Zhengyu Yang; Ruijun Xu; Yonggang Duan; Jiajia Lin; Xiuqing Cui; Chuangang Fan; Yun Zhou; Wei Bao; Lei Jin; Yuewei Liu
Journal:  Endocrine       Date:  2021-08-07       Impact factor: 3.633

8.  Can we use serum Anti-Mullerian hormone to differentiate the diagnosis between polycystic ovary syndrome patients and healthy women with polycystic ovarian morphology and regular menstrual cycles.

Authors:  Hüseyin Aydoğmuş; Sefa Kelekçi; Ferhan Elmalı; Serpil Aydoğmuş
Journal:  Saudi Med J       Date:  2018-10       Impact factor: 1.484

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.